Talvy | $2,000,000 | (Mar 11, 2026)
Verdant Impact | $3,000,000 | (Mar 11, 2026)
Sigma360 | $17,000,000 | (Mar 11, 2026)
Certified by Founder
Lodge
DalCor Pharmaceuticals
start up
Canada
- Montreal, Québec
- 22/09/2023
- Series D
- $80,000,000
DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients.
- Industry Biotechnology Research
- Website https://dalcorpharma.com/
- LinkedIn https://www.linkedin.com/company/dalcor-pharmaceuticals/about/
R2 Wireless | $5,000,000 | (Mar 11, 2026)
Imperium Technologies, Inc | $2,000,000 | (Mar 11, 2026)
Lux Aeterna | $10,000,000 | (Mar 11, 2026)
Amigo | $11,000,000 | (Mar 11, 2026)
Axiom Trust Company | $11,800,000 | (Mar 11, 2026)
Sandbar | $23,000,000 | (Mar 11, 2026)
Jazz | $61,000,000 | (Mar 11, 2026)
PactFi | $25,000,000 | (Mar 11, 2026)
Advocacy | $3,500,000 | (Mar 10, 2026)